subject: Cardiac Toxicity Of Anticancer Drugs And Control Strategies [print this page] Anticancer drugs may cause cardiovascular complications such as heart failure, myocardial ischemia, hypertension and arrhythmia. Among them, heart failure is the most serious and most common cardiac toxicity. Serious cardiac toxicity can have a direct impact on the prognosis of cancer patients. So it has become a common concern for cardiologists and cancer experts. With the population aging and the increase of tumor incidence, understanding and correct handling of the cardiac toxicity of anticancer drugs is essential for the treatment of tumor patients. Pharmaceutical raw materials suppliers have paid great efforts in developing the drugs.
Anticancer drug-induced cardiomyopathy and Drug cumulative dose, the use of cycle and used in conjunction with the cardiac toxicity of chemotherapy drugs and other factors, can lead to left ventricular dysfunction (LVD) and (or) heart failure (HF). Table 1 for anticancer drugs LVD / HF incidence.
Anthracycline-induced cardiotoxicity can be divided into acute, early slow progress and late slow progress of the three types. The incidence of acute cardiac toxicity
